home / stock / ptgx / ptgx articles
Thursday, Takeda Pharmaceutical Co Ltd (NYSE:TAK) reported a third-quarter 2023 core net profit of ¥235.9 billion, down 9.4% and&nb...
Suneel Gupta, Chief Development Officer at Protagonist Therapeutics (NASDAQ:PTGX), reported a large exercise of company stock options on October 23...
Dinesh V. Patel, Ph.D., President and CEO at Protagonist Therapeutics (NASDAQ:PTGX), reported a large exercise of company stock options on October ...
News, Short Squeeze, Breakout and More Instantly...
Protagonist Therapeutics Inc. Company Name:
PTGX Stock Symbol:
NASDAQ Market:
Protagonist Therapeutics Inc. Website:
Protagonist Therapeutics Set to Join S&P SmallCap 600 Protagonist Therapeutics Set to Join S&P SmallCap 600 PR Newswire NEW YORK , June 27, 2024 /PRNewswire/ -- Protagonist Therapeutics Inc. (NASD: PTGX) will replace Encore Wire Corp. (NASD: WIRE) in ...
Long term follow-up from REVIVE Phase 2 study up to 3 years shows durable hematocrit (Hct) control (< 45%), decreased phlebotomy use, long-term tolerability, and no new safety signals in patients with polycythemia vera Patients receiving rusfertide in the open-label extension of the REVIV...